Vigonvita Life Sciences Co., Ltd. (HKG:2630)
Hong Kong · Delayed Price · Currency is HKD 82.40
+0.25 (0.30%)
Oct 7, 2026, 3:51 PM HKT
Vigonvita Life Sciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| 217.26 | 102.1 | 11.83 | 199.65 | |
Revenue Growth | - | 762.88% | -94.07% | - |
Cost of Revenue | 30.45 | 21.42 | 8.35 | 6.01 |
Gross Profit | 186.81 | 80.68 | 3.49 | 193.64 |
Selling, General & Admin | 264.54 | 209.27 | 69.39 | 52.51 |
Research & Development | 185.53 | 202.5 | 134.86 | 131.3 |
Operating Expenses | 452.19 | 414.96 | 207.15 | 186.39 |
Operating Income | -265.37 | -334.28 | -203.66 | 7.25 |
Interest Expense | -14.44 | -13.36 | -16.16 | -7.2 |
Interest & Investment Income | 2.98 | 0.66 | 0.71 | 1.79 |
Currency Exchange Gain (Loss) | -10.91 | -2.85 | 0.24 | 0.25 |
Other Non Operating Income (Expenses) | -13.53 | -6.38 | 1.21 | 4.34 |
EBT Excluding Unusual Items | -301.27 | -356.2 | -217.67 | 6.43 |
Gain (Loss) on Sale of Investments | -4.28 | -0.71 | 0.22 | - |
Gain (Loss) on Sale of Assets | - | - | -0.04 | - |
Other Unusual Items | - | - | -0.16 | - |
Pretax Income | -305.55 | -356.9 | -217.64 | 6.43 |
Income Tax Expense | - | 0.21 | - | - |
Earnings From Continuing Operations | -305.55 | -357.11 | -217.64 | 6.43 |
Minority Interest in Earnings | 0.78 | 1.39 | 6.24 | 5.66 |
Net Income | -304.78 | -355.72 | -211.4 | 12.09 |
Net Income to Common | -304.78 | -355.72 | -211.4 | 12.09 |
Net Income Growth | - | - | - | - |
Shares Outstanding (Basic) | 161 | 153 | 146 | 145 |
Shares Outstanding (Diluted) | 161 | 153 | 146 | 145 |
Shares Change | 7.22% | 4.87% | 0.69% | - |
EPS (Basic) | -1.89 | -2.33 | -1.45 | 0.08 |
EPS (Diluted) | -1.89 | -2.33 | -1.45 | 0.08 |
EPS Growth | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Free Cash Flow | - | -256.64 | -186.53 | -56.05 |
Free Cash Flow Per Share | - | -1.68 | -1.28 | -0.39 |
Gross Margin | 85.98% | 79.02% | 29.47% | 96.99% |
Operating Margin | -122.14% | -327.41% | -1721.30% | 3.63% |
Profit Margin | -140.28% | -348.42% | -1786.71% | 6.05% |
Free Cash Flow Margin | - | -251.38% | -1576.46% | -28.07% |
EBITDA | -239.58 | -310.27 | -183.23 | 14.12 |
EBITDA Margin | -110.27% | - | - | 7.07% |
D&A For EBITDA | 25.79 | 24.01 | 20.44 | 6.87 |
EBIT | -265.37 | -334.28 | -203.66 | 7.25 |
EBIT Margin | -122.14% | - | - | 3.63% |